Orlistat CAS 96829-58-2 for the treatment of obesity and hyperlipidemia

Profile

Product Name: Orlistat

Synonyms: (S)-2-FORMYLAMINO-4-METHYL-PENTANOIC ACID (S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]-DODECYL ESTER;RO-18-0647;(-)-TETRAHYDROLIPSTATIN;ORLISTAT;N-FORMYL-L-LEUCINE (1S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]DODECYL ESTER;XENICAL;(-)-Tetrahydrolipstatin(EquivalentToOrlistat);Orlipastat

CAS: 96829-58-2

MF: C29H53NO5

MW: 495.73

Product Categories: Pharmaceutical Raw Materials;Miscellaneous Biochemicals;API;Antiobesity Agent;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Amino Acids & Derivatives;Heterocycles;ACTOS;Other APIs;Lipid-lowering medicine reducing weight

Mol File: 96829-58-2.mol  

Description

Tetrahydrolipstatin (orlistat) is a semi-synthetic derivative of lipstatin, a metabolite isolated from Streptomyces toxytricini. Tetrahydrolipstatin acts as a potent, irreversible inhibitor of pancreatic lipase. In vivo, it blocks the absorption of triglycerides while allowing fatty acid absorption. Tetrahydrolipstatin is widely used for the treatment of obesity.

Application

Clinically orlistat can be applied to the treatment of obesity and hyperlipidemia. Under normal circumstances, it can be subject to oral administration at a dose of 120 mg for three times per day. Take it during the meal or 1 hour after a meal. After 2 weeks of administration, the body weight can begin to decline. It can be taken continuously for 6 to 12 months. If the dose is increased to above 400 mg daily, the effect will no longer be further enhanced.  

Orlistat is a long-acting, specific gastrointestinal lipase inhibitor that prevents triglycerides from hydrolyzing to absorb free fatty acids and monoacylglycerols, which are not absorbed, thereby reducing caloric intake and controlling body weight. When used as an over-the-counter drug for self-medication, orlistat is indicated for obese or overweight patients (BMI ≥ 24, approximation calculated as weight / height 2). In order to achieve good results, taking orlistat should be combined with low-calorie diet and adequate exercise. For consumers with a BMI of less than 24, weight control should not be used with orlistat to achieve weight loss.